Drug safety: Experience with risperidone

Advances in Therapy

Volumn 14, Issue 5, 1997, Pages 262-266

  Tooley, Peter J H ^a   Zuiderwijk, Peter ^b  

^a Janssen Cilag Ltd   (United Kingdom)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Neuroleptic agents; Risperidone; Safety

Indexed keywords

NEUROLEPTIC AGENT; PROLACTIN; RISPERIDONE;

ARTICLE; BLOOD DYSCRASIA; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; NEUROLEPTIC MALIGNANT SYNDROME; SCHIZOPHRENIA; SEDATION; TARDIVE DYSKINESIA;

EID: 0030657782     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Hirsch SR, Weinberger DR, eds. Schizophrenia. London: Blackwell Science; 1995:549,557.
2. Wilson JD et al, eds. Harrison's Principles of Internal Medicine. 12th ed. New York: McGraw-Hill; 1991:1-1026.
3. Bristow MF, Kohen D. Neuroleptic malignant syndrome (review). Br J Hosp Med. 1996;55:517-520.
4. Eberhard G. The extrapyramidal symptoms rating scale (ESRS) and its use in the evaluation of risperidone. J Drug Dev Clin Pract. 1996;7:269-279.
5. De Hert M. Suicide bij jonge schizofrene patienten. Doctoral thesis, October 1995. Acta Biomedica Lovaniensia 115; Leuven University Press, Leuven, the Netherlands.
6. Black DW et al, eds. Mortality in DSM-IIIR Schizophrenia. Schizophrenia Res. 1992;7:109-116.